Our corporate offices are located at 210 Main Street West, Baudette, Minnesota 56623.
−Removed: The facility, which we own, includes oral solid dose and liquid manufacturing and packaging, warehouse facilities, analytical, stability, and microbiological laboratory space, and employee office and mechanical space.
−Removed: We also own a manufacturing facility that includes oral solid dose manufacturing and packaging for pharmaceutical products that must be manufactured in a fully contained environment, warehouse facilities, and employee office and mechanical space.
−Removed: This facility is also located in Baudette, Minnesota.
−Removed: We also own a cold storage facility located in Baudette, Minnesota.
−Removed: In addition, we also own a facility in East Windsor, New Jersey, which includes manufacturing, warehousing, laboratory, product development, and employee office space.
−Removed: In addition, we own a manufacturing facility located in Oakville, Ontario that includes oral solid dose, semi-solids, and non-sterile liquid manufacturing and packaging, warehouse facilities, analytical, stability, and microbiological laboratory space, and employee office and mechanical space.
−Removed: On June 2, 2022, we announced that we intend to cease operations at our Oakville, Ontario, Canada manufacturing plant by the first quarter of 2023.
−Removed: This action is part of ongoing initiatives to capture operational synergies following our acquisition of Novitium in November 2021.
−Removed: We have transitioned the majority of products manufactured or packaged in Oakville to one of our three U.S.-based manufacturing sites and are on track to cease operations by the end of the first quarter 2023.
−Removed: We are seeking to find potential buyers for the Oakville site, though there can be no assurance as to when or if that will occur or the amount of any net proceeds that may be received.
−Removed: We lease spaces for warehouse and packaging activities in Baudette, Minnesota, office space in Minnetonka, Minnesota and East Windsor, New Jersey, and for research and development activities in Chennai, India.
−Removed: The leases will
−Removed: expire between 2025 and 2027.
−Removed: We recently purchased additional warehouse space in Baudette, Minnesota to support our ongoing operations.
+Added: The facility, which we own, includes oral solid dose, powder and liquid manufacturing and packaging, warehouse facilities, analytical, stability, and microbiological laboratory space, and employee office and mechanical space.
+Added: We own a manufacturing facility that includes oral solid dose manufacturing and packaging for pharmaceutical products that must be manufactured in a fully contained environment, warehouse facilities, and employee office and mechanical space, also located in Baudette, Minnesota.
+Added: We own a cold storage facility located in Baudette, Minnesota.
+Added: In addition, we own a facility in East Windsor, New Jersey, which includes manufacturing, warehousing, laboratory, product development, and employee office space, which was acquired as part of the acquisition of Novitium in November 2021.
+Added: We ceased operations at our subsidiary, ANI Pharmaceuticals Canada, Inc., a wholly owned subsidiary of the Company located in Oakville, Ontario, Canada as of March 31, 2023.
+Added: This action is part of ongoing initiatives to capture operational synergies following our acquisition of Novitium.
+Added: We have fully completed the transition of the products manufactured or packaged in Oakville to one of our three U.S.-based manufacturing sites.
+Added: On November 6, 2023, ANI Pharmaceuticals Canada Inc., entered into an agreement for the sale of the Oakville, Ontario manufacturing facility.
+Added: On December 22, 2023, the agreement was terminated by mutual agreement.
+Added: In February 2024, the Company entered into an agreement for the purchase and sale of the Oakville site, for a purchase price of 19.2 million Canadian Dollars, or approximately $ 14.2 million US Dollars, based on the current exchange rate.
+Added: The sale is expected to close in March 2024 ( see Note 19.
+Added: Subsequent Events, in the notes to the consolidated financial statements in Part II, Item 8 of this Annual Re port on Form 10-K).
+Added: We lease spaces for warehouse and packaging activities in East Windsor, New Jersey, and for research and development activities in Chennai, India.
+Added: In September 2022, we entered into a lease for office space in Princeton, New Jersey, which includes certain employees in our corporate, legal, human resources, business functions, and rare disease operations.
+Added: The leases will expire between 2025 and 2028.
+Added: During 2023, we have expanded our East Windsor, New Jersey facility to accommodate additional laboratory, product development, and employee office space.
We consider our leased and owned properties suitable and adequate for our current and foreseeable needs.
Legal Proceedings
−Removed: Our legal proceedings are discussed in Note 13.
−Removed: Commitments and Contingencies, in the notes to the consolidated financial statements in Part II, Item 8.
+Added: Our legal proceedings are dis cussed in Note 15.
+Added: Com mitments and Contingencies, in the notes to the consolidated financial statements in Part II, Item 8.
of this Annual Report on Form 10-K.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.